Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

1e41697d-1d03-461d-8e10-73af2d8bd770

—

2a6bdd33-e237-5abe-b099-db88b0df102f

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • DNA_REPAIR+0.500
  • E2F_TARGETS+0.500
  • INTERFERON_ALPHA_RESPONSE+0.500
  • MYC_TARGETS_V1+0.500
  • MYC_TARGETS_V2+0.500
  • ALLOGRAFT_REJECTION+0.400
  • INTERFERON_GAMMA_RESPONSE+0.400
  • OXIDATIVE_PHOSPHORYLATION+0.400
  • G2M_CHECKPOINT+0.300
  • PANCREAS_BETA_CELLS+0.300

Top 10 suppressed

  • ANGIOGENESIS-0.300
  • APICAL_SURFACE-0.300
  • NOTCH_SIGNALING-0.300
  • TGF_BETA_SIGNALING-0.300
  • UV_RESPONSE_DN-0.300
  • WNT_BETA_CATENIN_SIGNALING-0.300
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
  • HEDGEHOG_SIGNALING-0.200
  • KRAS_SIGNALING_DN-0.200
  • PROTEIN_SECRETION-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-D8-A1Y3-01A-11R-A157-07
breast-umap@18
—B0.893
2TCGA-D8-A1XL-01A-11R-A14M-07
breast-umap@18
—B0.877
3SRR8518297
breast-umap@18
—E0.859
4SRR8518323
breast-umap@18
—E0.849
5TCGA-GM-A3XL-01A-11R-A22U-07
breast-umap@18
—E0.849
6TCGA-C8-A1HG-01A-11R-A137-07
breast-umap@18
—B0.844
7992ce1bc-46a2-4f57-ac7a-c6368c69c67c
colon-landscapes@1
——0.832
8SRR11296765
colon-landscapes@1
——0.831
9SRR8518289
breast-umap@18
—E0.826
10SRR8518360
breast-umap@18
—E0.825

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 21 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
DNA_REPAIR0.500Idelalisib— uncovered
E2F_TARGETS0.500Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.500Inavolisib— uncovered
MYC_TARGETS_V10.500Inavolisib— uncovered
MYC_TARGETS_V20.500Idelalisib— uncovered
ALLOGRAFT_REJECTION0.400Idelalisib— uncovered
INTERFERON_GAMMA_RESPONSE0.400Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.400Remibrutinib— uncovered
G2M_CHECKPOINT0.300Inavolisib— uncovered
PANCREAS_BETA_CELLS0.300Cobimetinib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
ADIPOGENESIS0.100Inavolisib— uncovered
BILE_ACID_METABOLISM0.100Inavolisib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
FATTY_ACID_METABOLISM0.100Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.100Inavolisib— uncovered
PEROXISOME0.100Idelalisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.100Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.100Inavolisib— uncovered
SPERMATOGENESIS0.100Inavolisib— uncovered